Articles from HekaBio K.K.

HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device ‘Alpha DaRT (Diffusing Alpha Radiation Therapy),’ developed by Alpha Tau Medical Ltd. (Headquarters: Jerusalem, Israel) has received official approval in Japan. HekaBio led the approval process as the Designated Marketing Authorization Holder (DMAH) and will be responsible for launching the product in the Japanese market. With this approval, Japan becomes the first country in the world outside of Israel to approve Alpha DaRT. The product will be available in Japan for the treatment of unresectable locally advanced or recurrent head and neck cancer, offering a new therapeutic option for cases where conventional treatments have been insufficient. We would like to express our sincere appreciation to Dr. Jun Itami, who was affiliated with the National Cancer Center Hospital during the clinical trial and is currently serving as Director of the High-Precision Radiation Therapy Center at Shin-Matsudo Central General Hospital, as well as to all healthcare professionals for their valuable contributions throughout the approval process.